MA40894A - HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES - Google Patents

HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES

Info

Publication number: MA40894A
Authority: MA; Morocco
Prior art keywords: lymphocytes; target; production processes; heterodimeric immunoglobulins; heterodimeric
Prior art date: 2014-11-04

Application number

MA040894A

Other languages

French (fr)

Inventor

Jonathan Back

Samuel Hou

Rami Lissilaa

Romain Ollier

Darko Skegro

Original Assignee

Glenmark Pharmaceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-04

Filing date

2015-11-02

Publication date

2017-09-12

2014-11-04 Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en

2015-11-02 Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa

2017-09-12 Publication of MA40894A publication Critical patent/MA40894A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA040894A 2014-11-04 2015-11-02 HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES MA40894A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/EP2014/073738 WO2015063339A1 (en)	2013-11-04	2014-11-04	Production of t cell retargeting hetero-dimeric immunoglobulins
EP15167034		2015-05-08

Publications (1)

Publication Number	Publication Date
MA40894A true MA40894A (en)	2017-09-12

Family

ID=53059011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA040894A MA40894A (en)	2014-11-04	2015-11-02	HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES

Country Status (20)

Country	Link
EP (1)	EP3215541A1 (en)
JP (3)	JP2018501297A (en)
KR (1)	KR20170078831A (en)
CN (1)	CN107207596A (en)
AU (1)	AU2015341884B2 (en)
BR (1)	BR112017009263A2 (en)
CA (1)	CA2965745C (en)
CL (1)	CL2017001090A1 (en)
CO (1)	CO2017005240A2 (en)
EA (1)	EA039658B1 (en)
HK (1)	HK1244014A1 (en)
IL (1)	IL251848A0 (en)
MA (1)	MA40894A (en)
MX (1)	MX2017005814A (en)
MY (1)	MY186929A (en)
NZ (1)	NZ732019A (en)
PE (1)	PE20171041A1 (en)
PH (1)	PH12017500819A1 (en)
SG (1)	SG11201703313SA (en)
WO (1)	WO2016071355A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
CN105051069B (en)	2013-01-14	2019-12-10	Xencor股份有限公司	Novel heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
PL3406633T3 (en)	2013-07-25	2022-05-23	Cytomx Therapeutics Inc.	Multispecific antibodies, multispecific activatable antibodies and methods of using the same
EP3176185A1 (en)	2013-11-04	2017-06-07	Glenmark Pharmaceuticals S.A.	Production of t cell retargeting hetero-dimeric immunoglobulins
US9822186B2 (en)	2014-03-28	2017-11-21	Xencor, Inc.	Bispecific antibodies that bind to CD38 and CD3
BR112017001579A2 (en) *	2014-07-25	2017-11-21	Cytomx Therapeutics Inc	anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable cd3 antibodies and methods of use
US11773166B2 (en)	2014-11-04	2023-10-03	Ichnos Sciences SA	CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
EA037065B1 (en)	2014-11-26	2021-02-01	Ксенкор, Инк.	Heterodimeric antibodies that bind cd3 and cd38
LT3223845T (en)	2014-11-26	2021-08-25	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cd20
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
TWI796283B (en)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Antibody constructs for msln and cd3
TWI829617B (en)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Antibody constructs for flt3 and cd3
JP7058219B2 (en)	2015-12-07	2022-04-21	ゼンコアインコーポレイテッド	Heterodimer antibody that binds to CD3 and PSMA
EA039859B1 (en)	2016-02-03	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Bispecific antibody constructs binding egfrviii and cd3
RU2767357C2 (en)	2016-06-14	2022-03-17	Ксенкор, Инк.	Bispecific checkpoint inhibitors antibodies
EP3475304B1 (en)	2016-06-28	2022-03-23	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
SG10201912545PA (en) *	2017-04-24	2020-02-27	Ichnos Sciences SA	T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2018224441A1 (en) *	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-cd3 antibodies
US11319371B2 (en)	2017-06-05	2022-05-03	Numab Therapeutics AG	Anti-CD3 antibodies
AU2018280869A1 (en) *	2017-06-08	2020-01-16	Black Belt Therapeutics Limited	CD38 modulating antibody
WO2018224682A1 (en)	2017-06-08	2018-12-13	Tusk Therapeutics Ltd	Cd38 modulating antibody
EP3587445B1 (en)	2017-08-10	2023-12-13	Grifols Diagnostic Solutions Inc.	An oligomerization tag comprising an immunoglobulin fc region and a polyhis domain
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	Multispecific molecules that bind to bcma and uses thereof
US11236173B2 (en)	2017-08-16	2022-02-01	Black Belt Therapeutics Limited	CD38 antibody
US11542338B2 (en)	2017-08-16	2023-01-03	Black Belt Therapeutics Limited	CD38 modulating antibody
AU2018347607A1 (en)	2017-10-14	2020-03-26	Cytomx Therapeutics, Inc.	Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR20210075101A (en) *	2018-09-25	2021-06-22	아이크노스 사이언스 에스. 아.	Antibody quantification in biological samples
KR102353568B1 (en) *	2018-11-14	2022-01-20	주식회사 헬릭스미스	Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability
US20220089765A1 (en) *	2019-01-23	2022-03-24	Encefa	Cd31 competitors and uses thereof
WO2020182984A2 (en) *	2019-03-13	2020-09-17	Ichnos Sciences SA	Non-consensus glycosylation of bispecific antibodies
WO2020237173A1 (en) *	2019-05-23	2020-11-26	VelosBio Inc.	Anti-ror1/anti-cd3 bispecific binding molecules
JPWO2020250940A1 (en) *	2019-06-11	2020-12-17
CN110551222B (en) *	2019-08-27	2023-06-06	重庆市畜牧科学院	Novel bifunctional antibody and application thereof
CN112538114A (en) *	2019-09-20	2021-03-23	上海普铭生物科技有限公司	Anti-human CD38 antibody and application thereof
WO2021063330A1 (en) *	2019-09-30	2021-04-08	和铂医药(苏州)有限公司	Cd3-targeting antibody, bispecific antibody and use thereof
CN113493519B (en) *	2020-03-19	2022-12-27	浙江道尔生物科技有限公司	Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases
US20230212289A1 (en) *	2020-04-24	2023-07-06	Memorial Sloan Kettering Cancer Center	Anti-cd3 antibodies and uses thereof
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4168450A2 (en) *	2020-06-17	2023-04-26	Y-Mabs Therapeutics, Inc.	Cd38 antibodies for the treatment of human diseases
MX2023001962A (en)	2020-08-19	2023-04-26	Xencor Inc	Anti-cd28 and/or anti-b7h3 compositions.
US11859012B2 (en)	2021-03-10	2024-01-02	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and GPC3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2511297T3 (en) *	2004-02-06	2015-06-15	Morphosys Ag	Human anti-CD38 antibodies and their applications
CN101218256B (en) *	2005-03-23	2017-04-19	根马布股份公司	Antibodies against cd38 for treatment of multiple myeloma
CA2625681C (en) *	2005-10-12	2016-08-02	Morphosys Ag	Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) *	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
SI2975051T1 (en) *	2009-06-26	2021-08-31	Regeneron Pharmaceuticals, Inc.	Readily isolated bispecific antibodies with native immunoglobulin format
KR102380315B1 (en) *	2009-12-25	2022-03-29	추가이 세이야쿠 가부시키가이샤	Polypeptide modification method for purifying polypeptide multimers
JP6093696B2 (en) *	2010-06-09	2017-03-08	ゲンマブエー／エス	Antibody against human CD38
JOP20210044A1 (en) *	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	Anti-cd38 antibodies
SG10201602371VA (en) *	2011-03-25	2016-04-28	Glenmark Pharmaceuticals Sa	Hetero-dimeric immunoglobulins
US20150239991A1 (en) *	2012-09-25	2015-08-27	Glenmark Pharmaceuticals S.A.	Purification of hetero-dimeric immunoglobulins
ES2621377T3 (en) *	2012-11-05	2017-07-03	Morphosys Ag	Radiolabelled antibody and uses thereof
EP3176185A1 (en) *	2013-11-04	2017-06-07	Glenmark Pharmaceuticals S.A.	Production of t cell retargeting hetero-dimeric immunoglobulins

2015
- 2015-11-02 MA MA040894A patent/MA40894A/en unknown
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/en not_active Withdrawn
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/en unknown
- 2015-11-03 CA CA2965745A patent/CA2965745C/en active Active
- 2015-11-03 KR KR1020177015252A patent/KR20170078831A/en not_active Application Discontinuation
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/en unknown
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/en active Pending
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/en active Application Filing
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/en not_active Application Discontinuation
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/en active Pending
- 2015-11-03 EA EA201790961A patent/EA039658B1/en unknown
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/en unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/en unknown
2018
- 2018-03-12 HK HK18103440.0A patent/HK1244014A1/en unknown
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/en active Pending
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/en active Active

Also Published As

Publication number	Publication date
MX2017005814A (en)	2017-08-02
JP7403505B2 (en)	2023-12-22
IL251848A0 (en)	2017-06-29
CA2965745A1 (en)	2016-05-12
HK1244014A1 (en)	2018-07-27
EP3215541A1 (en)	2017-09-13
SG11201703313SA (en)	2017-05-30
PH12017500819A1 (en)	2017-10-02
CO2017005240A2 (en)	2017-10-31
CL2017001090A1 (en)	2018-01-05
EA039658B1 (en)	2022-02-22
EA201790961A1 (en)	2017-10-31
CA2965745C (en)	2023-12-05
NZ732019A (en)	2022-07-29
AU2015341884B2 (en)	2020-09-17
AU2015341884A1 (en)	2017-06-08
PE20171041A1 (en)	2017-07-19
JP2021184722A (en)	2021-12-09
BR112017009263A2 (en)	2018-01-30
JP2018501297A (en)	2018-01-18
KR20170078831A (en)	2017-07-07
WO2016071355A1 (en)	2016-05-12
CN107207596A (en)	2017-09-26
JP2019214582A (en)	2019-12-19
MY186929A (en)	2021-08-26

Publication	Publication Date	Title
MA40894A (en)	2017-09-12	HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES
IL252467A0 (en)	2017-07-31	Heterodimeric antibodies that bind cd3 and cd38
IL256803A (en)	2018-03-29	Novel anti-pd-l1 antibodies
IL255727A (en)	2018-01-31	Novel anti-pd-l1 antibodies
HK1246324A1 (en)	2018-09-07	Anti-pd-l1 antibodies
IL257062A (en)	2018-03-29	Novel anti-pd-1 antibodies
IL248007A0 (en)	2016-11-30	Bispecific antibodies that bind to cd38 and cd3
MA43389A (en)	2021-05-12	ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE
MA40889A (en)	2017-09-12	HEREODIMERIC IMMUNOGLOBULINS RE-TARGET LYMPHOCYTES
SG10201603721TA (en)	2017-12-28	Anti-CTLA-4 Antibodies
HK1251055A1 (en)	2019-01-18	Automated interpretation for the layout of structured multi-field files
RS62332B1 (en)	2021-10-29	Heterodimeric antibodies that bind cd3 and cd20
MA41375A (en)	2017-11-28	BISPECIFIC IGG ANTIBODIES AND THEIR PREPARATION PROCESSES
MA42829A (en)	2021-04-14	COMPOSITIONS DERIVED FROM PLACENTA AND PROCESSES FOR PRODUCING THEM
IL247322A0 (en)	2016-09-29	Complement factor bb antibodies
MA39915A (en)	2017-03-22	PLADIENOLIDE PYRIDINE COMPOUNDS AND PROCESSES FOR USE
IL247285A0 (en)	2016-09-29	Marburg monoclonal antibodies
MA44517A (en)	2019-02-06	RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND PROCESSES FOR PRODUCTION AND USE
DK3250491T3 (en)	2022-06-13	Product turner and placer
MA45831A (en)	2019-06-12	BED ANTI-BODY MONOCLONAL ANTIBODIES AND THEIR PRODUCTION AND USE PROCESSES
BR112017016027A2 (en)	2018-07-10	bakery product
DK3307076T3 (en)	2019-07-15	ROOT-PARTICLE PRODUCT
ZA201604024B (en)	2017-08-30	Improved feeding strategies and purification processes for monoclonal antibody production
GB201621446D0 (en)	2017-02-01	IL-11 antibodies
TH176441B (en)	2018-06-07	Production systems and production methods for nitrogen-containing products And products that were selected from fermented / cultured products